48,460
edits
Difference between revisions of "Immunohistochemical staining"
Jump to navigation
Jump to search
→One organ vs. another: +more
(→One organ vs. another: +more) |
|||
| Line 177: | Line 177: | ||
*CD207 (AKA Langerin) -- +ve in Langerhans histocytes.<ref>URL: [http://www.ncbi.nlm.nih.gov/omim/604862 http://www.ncbi.nlm.nih.gov/omim/604862]. Accessed on: 2 February 2011.</ref> | *CD207 (AKA Langerin) -- +ve in Langerhans histocytes.<ref>URL: [http://www.ncbi.nlm.nih.gov/omim/604862 http://www.ncbi.nlm.nih.gov/omim/604862]. Accessed on: 2 February 2011.</ref> | ||
==One organ | ==One organ versus another== | ||
===Cervix | ===Cervix versus uterus=== | ||
*Cervix (typically): CEA +ve,<ref name=pmid12647218>{{cite journal |author=Alkushi A, Irving J, Hsu F, ''et al.'' |title=Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray |journal=Virchows Arch. |volume=442 |issue=3 |pages=271-7 |year=2003 |month=March |pmid=12647218 |doi=10.1007/s00428-002-0752-4 |url=}}</ref> p16 +ve. | *Cervix (typically): CEA +ve,<ref name=pmid12647218>{{cite journal |author=Alkushi A, Irving J, Hsu F, ''et al.'' |title=Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray |journal=Virchows Arch. |volume=442 |issue=3 |pages=271-7 |year=2003 |month=March |pmid=12647218 |doi=10.1007/s00428-002-0752-4 |url=}}</ref> p16 +ve. | ||
** ... and ER -ve, PR -ve, vimentin -ve. | ** ... and ER -ve, PR -ve, vimentin -ve. | ||
| Line 184: | Line 184: | ||
** ... and CEA -ve, p16 -ve. | ** ... and CEA -ve, p16 -ve. | ||
===Liver versus bile duct=== | |||
===Liver | |||
Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | Intrahepatic cholangiocarcinoma (ICC) vs. hepatocellular carcinoma (HCC):<ref name=pmid19173916>[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma] Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H. Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Chinese. PMID 19173916.</ref> | ||
*ICC: CK19 (92.5%), MUC-1 (73.8%) +ve. | *ICC: CK19 (92.5%), MUC-1 (73.8%) +ve. | ||
*HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | *HCC: HepPar-1 (85.6%), CD34 (87.8%) +ve. | ||
===Prostate | ===Prostate versus bladder=== | ||
Prostate adenocarcinoma vs. urothelial carcinoma: | Prostate adenocarcinoma vs. urothelial carcinoma: | ||
*Prostate adenocarcioma: PSA +ve, PSAP +ve, AR +ve, CK7 -ve, CK20 -ve. | *Prostate adenocarcioma: PSA +ve, PSAP +ve, AR +ve, CK7 -ve, CK20 -ve. | ||
*Urothelial carcinoma: CK7 +ve, CK20 +ve, PSA -ve, PSAP -ve, AR -ve. | *Urothelial carcinoma: CK7 +ve, CK20 +ve, PSA -ve, PSAP -ve, AR -ve. | ||
===Breast versus ovary=== | |||
Breast carcinoma versus ovarian carcinoma: | |||
*Ovary: WT-1 +ve, PAX8 +ve.<ref name=pmid18724243>{{Cite journal | last1 = Nonaka | first1 = D. | last2 = Chiriboga | first2 = L. | last3 = Soslow | first3 = RA. | title = Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. | journal = Am J Surg Pathol | volume = 32 | issue = 10 | pages = 1566-71 | month = Oct | year = 2008 | doi = 10.1097/PAS.0b013e31816d71ad | PMID = 18724243 }}</ref> | |||
*Breast: BRST2 +ve. | |||
==Lymphomas== | ==Lymphomas== | ||